{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T23:55:58Z","timestamp":1774137358027,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T00:00:00Z","timestamp":1334793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T00:00:00Z","timestamp":1334793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Alzheimer\u2019s dementia (AD) and frontotemporal dementias (FTD) are common and their clinical differential diagnosis may be complicated by overlapping symptoms, which is why biomarkers may have an important role to play. Cerebrospinal fluids (CSF) A\u03b22-42 and 1-42 have been shown to be similarly decreased in AD, but 1-42 did not display sufficient specificity for exclusion of other dementias from AD. The objective of the present study was to clarify the diagnostic value of A\u03b22-42 peptides for the differential diagnosis of AD from FTD. For this purpose, 20 non-demented disease controls (NDC), 22 patients with AD and 17 with FTD were comparatively analysed by a novel sequential aminoterminally and carboxyterminally specific immunoprecipitation protocol with subsequent A\u03b2-SDS-PAGE\/immunoblot, allowing the quantification of peptides 1-38<jats:sup>ox<\/jats:sup>, 2-40 and 2-42 along with A\u03b2 1-37, 1-38, 1-39, 1-40, 1-40<jats:sup>ox<\/jats:sup> and 1-42. CSF A\u03b21-42 was decreased in AD as compared to NDC, but not to FTD. In a subgroup of the patients analyzed, the decrease of Abeta2-42 in AD was evident as compared to both NDC and FTD. A\u03b21-38 was decreased in FTD as compared to NDC and AD. For differentiating AD from FTD, A\u03b21-42 demonstrated sufficient diagnostic accuracies only when combined with A\u03b21-38. A\u03b22-42 yielded diagnostic accuracies of over 85\u00a0% as a single marker. These accuracy figures could be improved by combining A\u03b22-42 to A\u03b21-38. A\u03b22-42 seems to be a promising biomarker for differentiating AD from other degenerative dementias, such as FTD.<\/jats:p>","DOI":"10.1007\/s00702-012-0801-3","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T11:43:53Z","timestamp":1334749433000},"page":"805-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Cerebrospinal fluid amyloid-\u03b2 2-42 is decreased in Alzheimer\u2019s, but not in frontotemporal dementia"],"prefix":"10.1007","volume":"119","author":[{"given":"Mirko","family":"Bibl","sequence":"first","affiliation":[]},{"given":"Marion","family":"Gallus","sequence":"additional","affiliation":[]},{"given":"Volker","family":"Welge","sequence":"additional","affiliation":[]},{"given":"Hermann","family":"Esselmann","sequence":"additional","affiliation":[]},{"given":"Stefanie","family":"Wolf","sequence":"additional","affiliation":[]},{"given":"Eckart","family":"R\u00fcther","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,4,19]]},"reference":[{"key":"801_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/prca.200900166","volume":"3","author":"V Albertini","year":"2010","unstructured":"Albertini V, Bruno A, Paterlini A, Lista S, Benussi L, Cereda C, Binetti G, Ghidoni R (2010) Optimization protocol for amyloid-\u03b2 peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 3:352\u2013357","journal-title":"Proteomics Clin Appl"},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archneur.58.3.373","volume":"58","author":"N Andreasen","year":"2001","unstructured":"Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-A\u03b242 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373\u2013379","journal-title":"Arch Neurol"},{"key":"801_CR3","doi-asserted-by":"crossref","unstructured":"Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, R\u00fcther E, Kornhuber J, Wiltfang (2004) Cerebrospinal fluid (CSF) amyloid beta (A\u03b2) peptide patterns in Alzheimer\u2019s disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of A\u03b2 peptides. Electrophoresis 25:2912\u20132918","DOI":"10.1002\/elps.200305992"},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.mp.4001967","volume":"12","author":"M Bibl","year":"2007","unstructured":"Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J (2007a) Validation of amyloid-\u03b2 peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 12:671\u2013680","journal-title":"Mol Psychiatry"},{"key":"801_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00702-006-0618-z","volume":"114","author":"M Bibl","year":"2007","unstructured":"Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J (2007b) Reduced CSF carboxyterminally truncated A\u03b2 peptides in frontotemporal lobe degenerations. J Neural Transm 114:621\u2013628","journal-title":"J Neural Transm"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/prca.200800006","volume":"2","author":"M Bibl","year":"2008","unstructured":"Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J (2008) CSF amyloid-\u03b2 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin App 2:1548\u20131556","journal-title":"Proteomics Clin App"},{"key":"801_CR7","doi-asserted-by":"crossref","unstructured":"Bibl M, Gallus M, Welge V, Lehmann S, Sparbier K, Esselmann H, Wiltfang J (2011a) Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-\u03b2-peptides. Proteomics Clin Appl (in press)","DOI":"10.1002\/prca.201100082"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000322370","volume":"31","author":"M Bibl","year":"2011","unstructured":"Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, R\u00fcther E, Wiltfang J (2011b) Cerebrospinal fluid tau, p-tau 181 and amyloid-\u03b238\/40\/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 31:37\u201344","journal-title":"Dement Geriatr Cogn Disord"},{"key":"801_CR9","doi-asserted-by":"crossref","unstructured":"Bibl M., Gallus M, Welge V, Esselmann H, Wiltfang J (2011b) Aminoterminally truncated and oxidized amyloid-\u03b2 peptides in the cerebrospinal fluid of Alzheimer\u2019s dementia patients. J Alzheimers Dis (in press)","DOI":"10.3233\/JAD-2012-111796"},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease. NeuroRx 1:213\u2013225","journal-title":"NeuroRx"},{"key":"801_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun M, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Matthis CA, DeKosky ST, Morris JC, Holtzmann DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512\u2013519","journal-title":"Ann Neurol"},{"key":"801_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JAD-2011-110515","volume":"26","author":"A Gabelle","year":"2011","unstructured":"Gabelle A, Roche S, G\u00e9ny C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Boulanghien J, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Perret-Liaudet A, Touchon J, Lehmann S (2011) Decreased sA\u03b2PP\u03b2, A\u03b238, and A\u03b240 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 26:553\u2013563","journal-title":"J Alzheimers Dis"},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1212\/WNL.58.11.1585","volume":"58","author":"D Galasko","year":"2002","unstructured":"Galasko D, Marder K (2002) Picking away at frontotemporal dementia. Neurology 58:1585\u20131586","journal-title":"Neurology"},{"key":"801_CR14","doi-asserted-by":"publisher","first-page":"697036","DOI":"10.1155\/2011\/697036","volume":"2011","author":"R Ghidoni","year":"2011","unstructured":"Ghidoni R, Paterlini A, Albertini V, Stoppani E, Binetti G, Fuxe K, Benussi L, Agnati LF (2011) A window into the heterogeneity of human cerebrospinal fluid A\u03b2 peptides. J. Biomed Biotechnol 2011:697036","journal-title":"J. Biomed Biotechnol"},{"key":"801_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885\u2013890","journal-title":"Biochem Biophys Res Commun"},{"key":"801_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.neuroscience.2006.08.027","volume":"143","author":"A G\u00fcntert","year":"2006","unstructured":"G\u00fcntert A, D\u00f6beli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143:461\u2013475","journal-title":"Neuroscience"},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, M\u00f6ller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer\u2019s disease\u2014a comparative study. Arch Gen Psychiatry 61:95\u2013102","journal-title":"Arch Gen Psychiatry"},{"key":"801_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwald HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD-patients using \u00df-amyloid (1-42) and tau levels in CSF. Neurology 52:1555\u20131562","journal-title":"Neurology"},{"key":"801_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","volume":"120","author":"ME Larson","year":"2012","unstructured":"Larson ME, Lesn\u00e8 SE (2012) Soluble A\u03b2 oligomer production and toxicity. J Neurochem 120:125\u2013139","journal-title":"J Neurochem"},{"key":"801_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"801_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol 38:643\u2013648","journal-title":"Ann Neurol"},{"key":"801_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 51:1546\u20131554","journal-title":"Neurology"},{"key":"801_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/pr050475v","volume":"4","author":"E Portelius","year":"2006","unstructured":"Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 4:1010\u20131016","journal-title":"J Proteome Res"},{"key":"801_CR24","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1021\/pr0703627","volume":"11","author":"E Portelius","year":"2007","unstructured":"Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 11:4433\u20134439","journal-title":"J Proteome Res"},{"key":"801_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000203774","volume":"6","author":"E Portelius","year":"2009","unstructured":"Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K (2009) Identification of novel APP\/A\u03b2 isoforms in human cerebrospinal fluid. Neurodegener Dis 6:87\u201394","journal-title":"Neurodegener Dis"},{"key":"801_CR26","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1212\/WNL.58.11.1622","volume":"58","author":"M Riemenschneider","year":"2002","unstructured":"Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, F\u00f6rstl H, Kurz A (2002) Tau and A\u03b242 protein in CSF of patients with frontotemporal degeneration. Neurology 58:1622\u20131628","journal-title":"Neurology"},{"key":"801_CR205","doi-asserted-by":"publisher","first-page":"14412","DOI":"10.1002\/chem.201002878","volume":"16","author":"H Schieb","year":"2010","unstructured":"Schieb H, Weidlich S, Schlechtingen G, Linning P, Jennings G, Gruner M, Wiltfang J, Klafki HW, Kn\u00f6lker HJ (2010) Structural design, solid-phase synthesis and activity of membrane-anchored \u03b2-secretase inhibitors on A\u03b2 generation from wild-type and Swedish-mutant APP. Chemistry 16:14412\u201314423","journal-title":"Chemistry"},{"key":"801_CR206","doi-asserted-by":"publisher","first-page":"33747","DOI":"10.1074\/jbc.M111.246561","volume":"286","author":"H Schieb","year":"2011","unstructured":"Schieb H, Kratzin H, Jahn O, M\u00f6bius W, Rabe S, Staufenbiel M, Wiltfang J, Klafki HW (2011) Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. J Biol Chem 286:33747\u201333758","journal-title":"J Biol Chem"},{"key":"801_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1471-4159.2009.05950.x","volume":"109","author":"J Sevalle","year":"2009","unstructured":"Sevalle J, Amoyel A, Robert P, Fournie-Zaluski MC, Roques B, Checler F (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid \u03b2-peptide. J Neurochem 109:248\u2013256","journal-title":"J Neurochem"},{"key":"801_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s007020070079","volume":"107","author":"M Sj\u00f6gren","year":"2000","unstructured":"Sj\u00f6gren M, Minthon L, Davidson P, Granerus AK, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K (2000) CSF levels of tau, \u03b2-amyloid1\u201342 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 107:563\u2013579","journal-title":"J Neural Transm"},{"key":"801_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2249.2002.01905.x","volume":"129","author":"AH Tammer","year":"2002","unstructured":"Tammer AH, Coia G, Cappai R, Fuller S, Masters CL, Hudson P, Underwood JR (2002) Generation of a recombinant Fab antibody reactive with the Alzheimer\u2019s disease related A\u03b2 peptide. Clin Exp Immunol 129:453\u2013463","journal-title":"Clin Exp Immunol"},{"key":"801_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0197-4580(98)00022-0","volume":"19","author":"The Working Group on:\u201cMolecular and Biochemical Markers of Alzheimer\u2019s Disease\u201d","year":"1998","unstructured":"The Working Group on:\u201cMolecular and Biochemical Markers of Alzheimer\u2019s Disease\u201d (1998) Consensus report of the Working Group on: \u201cMolecular and Biochemical Markers of Alzheimer\u2019s Disease\u201d. The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group. Neurobiol Aging 19:109\u2013116","journal-title":"Neurobiol Aging"},{"key":"801_CR31","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1373\/clinchem.2005.051201","volume":"9","author":"H Vanderstichele","year":"2005","unstructured":"Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E (2005) Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 9:1650\u20131660","journal-title":"Clin Chem"},{"key":"801_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00702-008-0177-6","volume":"116","author":"V Welge","year":"2009","unstructured":"Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M (2009) Combined CSF tau, p-tau181 and amyloid-\u03b2 38\/40\/42 for diagnosing Alzheimer\u2019s disease. J Neural Transm 116:203\u2013212","journal-title":"J Neural Transm"},{"key":"801_CR33","doi-asserted-by":"publisher","first-page":"42645","DOI":"10.1074\/jbc.M102790200","volume":"276","author":"J Wiltfang","year":"2001","unstructured":"Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, R\u00fcther E, Kornhuber J, Annaert W, De Strooper B, Saftig P (2001) Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer\u2019s disease and its generation in PS1 knockout cells. J Biol Chem 276:42645\u201342657","journal-title":"J Biol Chem"},{"key":"801_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1046\/j.1471-4159.2002.00818.x","volume":"81","author":"J Wiltfang","year":"2002","unstructured":"Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmid B, Klafki H-W, Maler M, Dyrks T, Bienert M, Beyermann M, R\u00fcther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37\/38\/39 in addition to 1-40\/42 in Alzheimer\u2019s disease and patients with chronic neuroinflammation. J Neurochem 81:481\u2013496","journal-title":"J Neurochem"},{"key":"801_CR35","first-page":"1407","volume":"313","author":"World Medical Organisation","year":"1996","unstructured":"World Medical Organisation (1996) Declaration of Helsinki. BMJ 313:1407\u20131431","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1007\/s00702-018-1914-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000}}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0801-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-012-0801-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00702-012-0801-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0801-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:43:55Z","timestamp":1630521835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-012-0801-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s00702-012-0801-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]},"assertion":[{"value":"21 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}